Navigation Links
Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
Date:10/28/2008

to HIV infection.

"These data provide good support for the evaluation of our first ZFN-based ZFP Therapeutic in man," commented Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "It was observed more than ten years ago that individuals carrying the natural CCR5-delta32 mutation were highly resistant to infection by HIV. Consequently, a variety of small molecule and antibody approaches have been tested as potential therapeutics. However, a small molecule or antibody approach requires the constant presence of a sufficiently high concentration of drug to block therapeutically relevant numbers of the CCR5 protein, which is present in thousands of copies on the surface of each T-cell and other tissues in the body. We believe that our ZFN technology provides an approach that circumvents the dosing and potential toxicity issues of a systemic therapy. By specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs, we can generate a population of R5-tropic HIV-resistant T-cells.

We have shown that these ZFN-modified human cells are made permanently resistant to infection by HIV. Furthermore, the cells selectively survive and expand in an animal after HIV infection, providing a reservoir of healthy and uninfectable immune cells. In a patient, such cells could be available to fight both opportunistic infections characteristic of AIDS and HIV itself. The modified cells exhibited the expected properties of normal CD4 T-cells. These data also demonstrate that ZFN-modified human CD4 T-cells can be produced in the quantities required for the translation of this program into the clinic. We intend to file an investigational new drug (IND) application for this ZFP Therapeutic this year and begin a clinical trial as soon as possible."

Data Reported in the ICAAC/IDSA Presentation

The reported results demonstrate that a one-time exposure to CCR5-specif
'/>"/>

SOURCE Sangamo BioSciences, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
4. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
5. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
6. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
7. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
8. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
9. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
10. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014 /PRNewswire/ ... announced today that Medtronic, Inc. (NYSE: ... to the U.S. Food and Drug Administration (FDA) ... II implantable drug infusion system (including a newly ... ® (treprostinil) Injection delivered intravenously to patients ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... 23, 2014 Earlier this year in ... Sherley, director of the Adult Stem Cell Technology Center, ... overlooked and under appreciated unique property of adult tissue ... Stem Cells: Misunderstood in the Past, Important for the ... participants. He gave the address at the 4th ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... , COLUMBIA, Md., Aug. 19 Martek Biosciences Corporation ... results of its third quarter of fiscal 2009 on September 2, 2009, ... 4:45 p.m. ET Martek will conduct a conference call to discuss these ... live via webcast by visiting Martek,s web site at http://investors.martek.c ...
... , , , , ... WASHINGTON, Aug.19 A scholarly analysis of the keystone of indirect ... science fell far short of acceptable scientific standards. Professor John Mathews and ... exhaustive analysis of Searchinger et al. which revealed that the ...
... LAFAYETTE, Ind. - Researchers are adapting the same methods ... beams for a new class of "nanolithography" required to ... light to create the fine features in computer chips ... image of a mask onto a light-sensitive material, then ...
Cached Biology Technology:Analysis of Biofuels Indirect Land Use Effects Finds the Science Lacking: 'Too Diffuse and Subject To Too Many Arbitrary Assumptions To Be Useful for Rule-making.' 2Analysis of Biofuels Indirect Land Use Effects Finds the Science Lacking: 'Too Diffuse and Subject To Too Many Arbitrary Assumptions To Be Useful for Rule-making.' 3Nuclear fusion research key to advancing computer chips 2Nuclear fusion research key to advancing computer chips 3
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading ... study that pinpoints fine-scale differences in genetic ancestry of ... . Since immigrants first arrived more than ... has served as a meeting place for ... history and the ongoing mixing of peoples with African, ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Upton, NY -- An international team of researchers from ... the genomes of two important laboratory strains of E. ... other to produce proteins for basic research or practical applications. ... open a window to a deeper understanding of classical research ...
... 20, 2009Doctor of the Heart: My Life in Medicine ... best-selling author, and popular television commentator. Published by Mary ... account of his long and extraordinary career ( www.liebertpub.com/heart ... often referred to as "America,s Doctor." "Through his works ...
... disease for which there,s a proven cure, but nobody makes ... many around the world face every day and one Rice ... Internet. The Cure for Needy Project ( http://www.cureforneedy.org ... optimize small-molecule medications for orphaned diseases those for which ...
Cached Biology News:Genomes of 2 popular research strains of E. coli sequenced 2Genomes of 2 popular research strains of E. coli sequenced 3Just published: 'Doctor of the Heart: My Life in Medicine,' by Isadore Rosenfeld, M.D. 2Rice opens 'Cure for Needy' on the Web 2Rice opens 'Cure for Needy' on the Web 3
Fluorescein-CSCSSLMDKECVYFCHLDIIW (Disulfide bridge: 1-15 and 3-11)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
VMAT 2 (N-19)...
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: